AYTU BIOPHARMA, INC Deferred Tax Assets, Capital Loss Carryforwards
AYTU BIOPHARMA, INC (AYTU) had Deferred Tax Assets, Capital Loss Carryforwards of $5.79 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCapitalLossCarryforwards · last filed 2026-09-22
- 2026-06-30: Deferred Tax Assets, Capital Loss Carryforwards $5.79M.
- 2025-06-30: Deferred Tax Assets, Capital Loss Carryforwards $0.00.
- 2020-06-30: Deferred Tax Assets, Capital Loss Carryforwards $203.00K.
- 2019-06-30: Deferred Tax Assets, Capital Loss Carryforwards $203.00K.
| Period end | Deferred Tax Assets, Capital Loss Carryforwards |
|---|---|
| 2026-06-30 | $5.79M 10-K · filed 2026-09-22 |
| 2025-06-30 | $0.00 10-K · filed 2026-09-22 |
| 2020-06-30 | $203.00K 10-K · filed 2020-10-06 |
| 2019-06-30 | $203.00K 10-K · filed 2020-10-06 |
| 2018-06-30 | $204.00K 10-K · filed 2019-09-26 |
| 2017-06-30 | $385.00K 10-K · filed 2018-09-06 |
| 2016-06-30 | $0.00 10-K · filed 2017-08-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |